Serum sex hormone-binding globulin and testosterone in relation to cardiovascular disease risk factors in young men: a population-based study

D Canoy, T M Barber¹,², A Pouta², A L Hartikainen², M I McCarthy⁴,⁵, S Franks⁶, M R Järvelin²,⁷,⁸,⁹,¹⁰, J S Tapanainen³,¹¹, A Ruokonen¹²,¹³, I T Huhtaniemi⁶ and H Martikainen³

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UK, ¹Department of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, UK, ²Department of Children and Young People and Families, National Institute for Health and Welfare, Oulu, Finland, ³Department of Obstetrics and Gynaecology, Oulu University Hospital and University of Oulu, Oulu, Finland, ⁴Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK, ⁵Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK, ⁶Department of Surgery and Cancer, Imperial College London, Institute of Reproductive and Developmental Biology, London, UK, ⁷Department of Epidemiology and Biostatistics, Imperial College London, MRC-Health Protection Agency Centre for Environment and Health, and School of Public Health, London, UK, ⁸Institute of Health Sciences, University of Oulu, Oulu, Finland, ⁹Biocenter Oulu, University of Oulu, Oulu, Finland, ¹⁰Unit of Primary Care, Oulu University Hospital, Oulu, Finland, ¹¹Department of Obstetrics and Gynaecology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland, ¹²Department of Clinical Chemistry, University of Oulu, Oulu, Finland and ¹³NorLab Oulu, Oulu University Hospital, Oulu, Finland

Correspondence should be addressed to D Canoy
Email dexter.canoy@ceu.ox.ac.uk

Abstract

Objective: Reduced sex hormone-binding globulin (SHBG) concentration predicts insulin resistance and type 2 diabetes, but its association with cardiovascular disease (CVD) risk is unclear. We examined the association between SHBG and cardiovascular risk factors, independently of total testosterone (TT), in young men.

Design: Observational, cross-sectional study.

Setting: General community.

Participants: The study included 2716 men aged 31 years in the Northern Finland Birth Cohort in 1996 with clinical examination data and fasting blood samples.

Outcome variables: Blood pressure (BP), lipids and C-reactive protein (CRP) as biological CVD risk markers.

Results: SHBG concentration was significantly and inversely related to systolic and diastolic BP, triglycerides and CRP, but positively to HDL cholesterol after adjusting for insulin, BMI, waist circumference, smoking, education and physical activity (all P < 0.05). These linearly graded associations persisted with additional adjustment for TT. SHBG was significantly associated with total cholesterol only with adjustment for covariates and TT (P < 0.05). The direction and magnitude of associations between TT and risk factors were variable, but further adjustment for insulin, adiposity and SHBG showed positive associations between TT and BP, total and LDL-cholesterol and triglycerides and an inverse association with CRP (all P < 0.05), but its relation with HDL-cholesterol was no longer significant.

Conclusions: In this cohort of young adult men, higher SHBG concentration was associated with a more favourable CVD risk profile, independently of TT. SHBG concentration modified the associations of TT with CVD risk factors.
Introduction

First reported in 1967 (1), sex hormone-binding globulin (SHBG) is the specific binding protein for sex steroids in the blood plasma and it regulates the availability of free testosterone (FT) and oestradiol to hormone-responsive tissues and their metabolic clearance rate (2, 3). In men, over 40% of total testosterone (TT) in circulation is bound to SHBG. Although SHBG has traditionally been considered a passive carrier protein, it could have an important biological function of its own. It is known to modify local steroid hormone effects (4) by interacting specifically with high-affinity receptors on cell membranes and participate in steroid hormone signal transduction at the cell membrane independently of the classical intracellular androgen receptors (2, 5, 6). However, the wider clinical implications of this function remain to be elucidated.

Numerous studies have shown that reduced blood concentrations of SHBG are associated with increased risk of insulin resistance, type 2 diabetes, obesity and the metabolic syndrome (7, 8, 9, 10, 11, 12, 13, 14, 15) but the role of SHBG in the aetiology of cardiovascular disease (CVD) remains unclear. Studies investigating associations between SHBG and cardiovascular risk have focused only on a few biological risk markers, such as dyslipidaemia, were based on relatively small sample sizes, or did not explore associations independently of adiposity and insulin (16, 17, 18, 19, 20, 21). As insulin is known to suppress hepatic production of SHBG (22) and its elevated concentration has been closely associated with dyslipidaemia, hypertension and incident coronary heart disease (23, 24), it may play a role in explaining the relationship between low SHBG and increased CVD risk. Further, testosterone is closely correlated with, and may influence, SHBG concentration (25, 26). As low testosterone is associated, albeit inconsistently, with insulin resistance, type 2 diabetes (7, 8, 9, 27, 28) and atherosclerosis (27, 29), it is therefore unclear if the observed associations between SHBG and CVD risk factors are simply explained by testosterone. We examined the relationship between SHBG and risk factors of CVD, independently of testosterone levels, in a population-based cohort of young adult men.

Subjects and methods

Study population

The Northern Finland Birth Cohort (NFBC) consists of 12 231 unselected births (representing 96.3% of all births) of women from the Finnish provinces of Oulu and Lapland in 1966 (30). The number of children born alive was 12 058 (52% boys). In 1997, we sent a health and lifestyle questionnaire to 97% of the birth cohort (at age 31 years), and invited those living in Northern Finland and in the Helsinki area (n=8463) for a clinical examination, of whom 6033 men and women attended and gave fasting blood samples. The current study sample is limited to men (n=2716) aged 31 years who had given informed consent, had attended clinical examination and had a blood sample taken for measurement of SHBG and testosterone concentrations. The questionnaires provided health and lifestyle data including information on smoking, educational qualification and physical activity. Of those who were invited to attend the clinical examination, we found no statistically significant difference in birth weight (P=0.99) nor in educational attainment (P=0.06) or cigarette smoking habit (P=0.39) at age 31 years when comparing men who attended the clinical examination with those who did not.

The University of Oulu Ethics committee approved the conduct of the study.

Anthropometric and biochemical measurements

We measured blood pressure (BP) (average of two separate measurements) taken with a mercury sphygmomanometer in a sitting position after 15 min of rest (31). We obtained anthropometric measurements including weight, height and waist circumference, and calculated BMI as weight/height^2. Participants gave blood samples between 0800 and 1100 h following an overnight fast, which were centrifuged immediately and the serum stored at −20°C. Assays were carried out within 7 days of the samples being taken. We analysed serum SHBG by immunofluorometric assay (Perkin Elmer-Wallac, Ltd, Turku, Finland) and serum testosterone by an automated chemiluminescence system (ACS-180, Ciba-Corning, Inc., Medfield, MA, USA), and calculated free testosterone (cFT) using Vermeulen’s equation (32). We analysed fasting insulin by radio-immunoassay (Pharmacia Diagnostics), fasting glucose by glucose dehydrogenase method (Granotest 250, Diagnostica Merck) and high sensitivity C-reactive protein (CRP) by an immunoenzymometric assay (Medix Biochemica, Espoo, Finland). We determined cholesterol (total, HDL and LDL) and triglycerides using a Hitachi 911 automatic analyser and commercial reagents (Boehringer Mannheim). Intra- and inter-assay coefficients of variation (CV) were 1.3 and 5.1% for SHBG, respectively,
and 4 and 5.6% for TT, respectively. For insulin, glucose, lipids and CRP, intra-assay CV did not exceed 5.3% and inter-assay CV did not exceed 7.6%. The sensitivities of TT and insulin assays were 0.35 nmol/l and 14.4 pmol/l respectively.

We defined those with metabolic syndrome as having any three of the following characteristics: waist circumference ≥ 94 cm, triglycerides ≥ 1.7 mmol/l, HDL-cholesterol < 1.0 mmol/l, systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg and plasma glucose ≥ 5.5 mmol/l (33).

**Statistical analysis**

We determined the separate relationships between SHBG and an intermediate risk marker of CVD using regression models. We log-transformed triglycerides, insulin and CRP values before linear regression analyses. We conducted similar analyses for TT and cFT, as well as analyses that used metabolic syndrome as the outcome variable. To examine systematically the impact of potential confounders, we analysed data by adjusting sequentially for smoking, education and physical activity and then additionally for fasting insulin and adiposity (BMI and waist circumference) in separate models. We also calculated the homeostatic assessment model for insulin resistance (HOMA-IR) (34) and examined the impact of using this parameter, rather than insulin, in our regression models.

To show the relative independent associations of SHBG and TT on cardiovascular risk outcomes, we adjusted these two exposure variables for each other in the multivariate regression models. We also examined the distribution of cardiovascular risk factors across SHBG and TT quartiles based on multivariate-adjusted models to demonstrate the magnitude of cardiovascular risk across the distribution of SHBG and TT in our study population. Estimates were presented with their standard error or 95% CI, and a P value < 0.05 was considered statistically significant. All analyses were conducted using the statistics package Stata 11 MP (College Station, TX, USA).

**Results**

In this cohort, mean (s.d.) SHBG, TT and calculated cFT were 33.3 (s.d. = 13.3) nmol/l, 21.6 (s.d. = 6.5) nmol/l and 481 (s.d. = 144) pmol/l respectively. Mean BMI was 25.2 (s.d. = 3.6) kg/m² and 8.4% of men were obese (BMI ≥ 30 kg/m²). Table 1 provides the distribution of characteristics across quartiles of SHBG. Higher SHBG quartiles

---

**Table 1** Characteristics of men aged 31 years in the NFBC 1966 study by SHBG concentration. Data presented as mean (s.d.) for continuous variables, except for triglycerides, insulin and C-reactive protein which are presented as median (25th to 75th percentile range), and percentage for categorical variables.

<table>
<thead>
<tr>
<th>SHBG (nmol/l)</th>
<th>&lt;24.1</th>
<th>24.1–31.5</th>
<th>31.6–40.4</th>
<th>&gt;40.4</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>682</td>
<td>679</td>
<td>677</td>
<td>678</td>
<td>2716</td>
</tr>
<tr>
<td>SHBG (nmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total testosterone (nmol/l)</td>
<td>16.8 (5.4)</td>
<td>20.2 (4.6)</td>
<td>22.6 (5.0)</td>
<td>26.8 (6.3)</td>
<td>21.6 (6.5)</td>
</tr>
<tr>
<td>Free testosterone (pmol/l)</td>
<td>478 (182)</td>
<td>490 (130)</td>
<td>486 (128)</td>
<td>469 (130)</td>
<td>481 (144)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.7 (4.0)</td>
<td>25.5 (3.0)</td>
<td>24.2 (2.9)</td>
<td>23.5 (2.9)</td>
<td>25.2 (3.6)</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>95.9 (10.4)</td>
<td>89.8 (8.3)</td>
<td>86.2 (8.1)</td>
<td>83.9 (7.9)</td>
<td>88.9 (9.8)</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>134.6 (13.2)</td>
<td>131.5 (12.9)</td>
<td>129.0 (12.5)</td>
<td>128.5 (12.9)</td>
<td>130.9 (13.1)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>85.3 (10.4)</td>
<td>80.9 (10.8)</td>
<td>79.4 (11.4)</td>
<td>78.1 (11.5)</td>
<td>80.9 (11.8)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>5.41 (1.04)</td>
<td>5.19 (1.02)</td>
<td>5.12 (1.00)</td>
<td>5.15 (0.97)</td>
<td>5.22 (1.01)</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td>3.37 (0.99)</td>
<td>3.23 (0.89)</td>
<td>3.17 (0.89)</td>
<td>3.17 (0.91)</td>
<td>3.23 (0.90)</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>1.28 (0.30)</td>
<td>1.39 (0.28)</td>
<td>1.45 (0.33)</td>
<td>1.53 (0.35)</td>
<td>1.41 (0.33)</td>
</tr>
<tr>
<td>Triglycerides (nmol/l)</td>
<td>1.52 (1.18)</td>
<td>1.14 (0.69)</td>
<td>0.98 (0.60)</td>
<td>0.91 (0.53)</td>
<td>1.11 (1.77)</td>
</tr>
<tr>
<td>Plasma glucose (mmol/l)</td>
<td>5.24 (0.59)</td>
<td>5.17 (0.44)</td>
<td>5.16 (0.70)</td>
<td>5.12 (0.63)</td>
<td>5.17 (0.60)</td>
</tr>
<tr>
<td>Serum insulin (pmol/l)</td>
<td>70.3 (34.4)</td>
<td>56.9 (23.0)</td>
<td>51.7 (20.8)</td>
<td>48.8 (17.9)</td>
<td>56.0 (25.1)</td>
</tr>
<tr>
<td>HOMA-IR index</td>
<td>2.69 (1.65)</td>
<td>1.99 (0.91)</td>
<td>1.77 (0.69)</td>
<td>1.70 (0.72)</td>
<td>2.04 (1.19)</td>
</tr>
<tr>
<td>C-reactive protein (mg/l)</td>
<td>1.00 (1.70)</td>
<td>0.70 (1.10)</td>
<td>0.60 (0.90)</td>
<td>0.50 (0.80)</td>
<td>0.70 (1.2)</td>
</tr>
<tr>
<td>% Low educational attainmenta (n)</td>
<td>17.6 (120)</td>
<td>16.6 (113)</td>
<td>17.6 (119)</td>
<td>18.4 (125)</td>
<td>17.6 (477)</td>
</tr>
<tr>
<td>% Low physical activity levelb (n)</td>
<td>63.3 (432)</td>
<td>55.1 (374)</td>
<td>56.1 (380)</td>
<td>54.0 (366)</td>
<td>57.1 (1552)</td>
</tr>
<tr>
<td>% Metabolic syndromec (n)</td>
<td>36.4 (248)</td>
<td>12.5 (85)</td>
<td>8.4 (57)</td>
<td>5.3 (36)</td>
<td>15.7 (426)</td>
</tr>
</tbody>
</table>

NFBC, Northern Finland Birth Cohort; SHBG, sex hormone-binding globulin; HOMA-IR, homeostasis model assessment-estimated insulin resistance.

aNo degree (university, secondary/polytechnic, vocational) or unfinished education.

bLess than twice a week of brisk physical activity of at least 30 min.

cWith any three of the following features: waist circumference ≥ 94 cm; triglycerides ≥ 1.7 mmol/l, HDL-cholesterol < 1.0 mmol/l, systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg, and plasma glucose ≥ 5.5 mmol/l.
SHBG, testosterone and the metabolic syndrome

We first examined the relation of SHBG and TT with metabolic syndrome as the outcome variable (Table 2). The odds ratio for metabolic syndrome decreased with increasing SHBG, independently of other factors including TT, with over 46% reduced risk associated with 10.6 nmol/l increase in SHBG concentration. While the risk for metabolic syndrome decreased with increasing TT, this relation did not persist when taking BMI into account. However, with additional adjustment for SHBG, the risk for metabolic syndrome increased with higher TT, with over 38% excess risk associated with 5.2 nmol/l increase in TT concentration. Thus, when mutually adjusting for each other (and taking into account other potential confounding factors), SHBG and TT showed independent and opposing associations with metabolic syndrome. Adjusting for smoking, education, physical activity and BMI, the odds ratios (95% CI) from the second to the fourth quartile of cFT, as compared with the lowest quartile, were 1.31 (0.89–1.92), 1.51 (1.04–2.20) and 2.47 (1.71–3.55), respectively, with 34% excess risk associated with 110 pmol/l increase in cFT concentration.

SHBG and cardiovascular risk factors

Table 3 gives the association between SHBG and cardiovascular risk factors. Adjusting for smoking, education, physical activity and fasting insulin, increasing SHBG concentration was significantly associated with decreasing BP, triglycerides and CRP as well as with increasing HDL-cholesterol (all $P$ for trend <0.001). These associations were attenuated with additional adjustment for BMI and waist circumference, but the relation remained significant except for total and LDL-cholesterol and systolic BP. With further adjustment for TT, the association persisted, with increasing SHBG associated with decreasing BP, total cholesterol, triglycerides and CRP, and increasing HDL-cholesterol (all $P$ for trend <0.05). SHBG was unrelated to LDL-cholesterol in models that adjusted for insulin, adiposity or TT. Findings were similar when we used HOMA-IR, instead of insulin, as a covariate in the regression model for each risk factor being studied.

Figures 1 and 2 show the relative difference in BP and lipids across the whole SHBG gradient, taking into account TT and other covariates (full values are shown in the online Supplementary Table S1, see section on metabolic syndrome potential confounding factors), SHBG and TT showed independent and opposing associations with metabolic syndrome.

### Table 2

Odds ratio (95% CI) for metabolic syndrome according to the quartiles of sex hormone-binding globulin (SHBG) or total testosterone in 2716 men aged 31 years in the NFBC 1966 study.

<table>
<thead>
<tr>
<th>SHBG (nmol/l)</th>
<th>Percentage with metabolic syndrome* (n)</th>
<th>Adjusted for smoking, education and physical activity</th>
<th>Additionally adjusted for BMI</th>
<th>Additionally adjusted for SHBG or total testosterone*</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;24.1 (n=682)</td>
<td>36.4 (248)</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>24.1–31.5 (n=679)</td>
<td>12.5 (85)</td>
<td>0.25 (0.19–0.33)</td>
<td>0.41 (0.30–0.56)</td>
<td>0.33 (0.24–0.47)</td>
</tr>
<tr>
<td>31.6–40.4 (n=677)</td>
<td>8.4 (57)</td>
<td>0.15 (0.11–0.21)</td>
<td>0.39 (0.28–0.57)</td>
<td>0.28 (0.19–0.42)</td>
</tr>
<tr>
<td>&gt;40.4 (n=678)</td>
<td>5.3 (36)</td>
<td>0.09 (0.06–0.13)</td>
<td>0.29 (0.19–0.45)</td>
<td>0.16 (0.10–0.27)</td>
</tr>
<tr>
<td>All (per 10.6 nmol/l)</td>
<td>15.7 (426)</td>
<td>0.42 (0.37–0.47)</td>
<td>0.65 (0.57–0.74)</td>
<td>0.54 (0.46–0.63)</td>
</tr>
<tr>
<td>Total testosterone (nmol/l)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;17.4 (n=687)</td>
<td>23.3 (160)</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>17.4–21.9 (n=678)</td>
<td>18.0 (122)</td>
<td>0.70 (0.53–0.92)</td>
<td>1.46 (1.05–2.03)</td>
<td>2.01 (1.42–2.83)</td>
</tr>
<tr>
<td>21.1–25.6 (n=674)</td>
<td>11.3 (76)</td>
<td>0.40 (0.30–0.55)</td>
<td>0.93 (0.65–1.34)</td>
<td>1.67 (1.12–2.48)</td>
</tr>
<tr>
<td>&gt;25.6 (n=677)</td>
<td>10.0 (68)</td>
<td>0.34 (0.25–0.46)</td>
<td>1.13 (0.77–1.66)</td>
<td>3.17 (2.06–5.03)</td>
</tr>
<tr>
<td>All (per 5.2 nmol/l)</td>
<td>15.7 (426)</td>
<td>0.68 (0.62–0.77)</td>
<td>1.00 (0.88–1.12)*</td>
<td>1.38 (1.20–1.60)</td>
</tr>
</tbody>
</table>

All $P$ for trend <0.001 except *$P$>0.05.

*With any three of the following features: waist circumference ≥94 cm, triglycerides ≥1.7 mmol/l, HDL-cholesterol <1.0 mmol/l, systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, and plasma glucose ≥5.56 mmol/l.

*SHBG and total testosterone mutually adjusted for each other in the model.
Table 3  Relative difference (β coefficient [95% CI]) in cardiovascular risk markers per 10.6 nmol/l higher sex hormone-binding globulin in 2716 men aged 31 years in the NFBC 1966 study.

<table>
<thead>
<tr>
<th>Cardiovascular risk markers</th>
<th>Adjusted for smoking, education and physical activity</th>
<th>Additionally adjusted for fasting insulin</th>
<th>Additionally adjusted for BMI and waist circumference</th>
<th>Additionally adjusted for total testosterone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>−2.1 (−2.6 to −1.7)*</td>
<td>−1.4 (−1.9 to −1.0)*</td>
<td>−0.5 (−0.9 to 0.0)</td>
<td>−1.0 (−1.5 to −0.4)†</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>−2.3 (−2.7 to −1.9)*</td>
<td>−1.5 (−2.0 to −1.1)*</td>
<td>−0.6 (−1.1 to −0.2)†</td>
<td>−1.1 (−1.6 to −0.6)*</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>−0.09 (−0.12 to −0.05)*</td>
<td>−0.03 (−0.07 to 0.00)</td>
<td>0.02 (−0.02 to 0.05)</td>
<td>0.05 (−0.09 to −0.01)†</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>−0.06 (−0.10 to −0.03)*</td>
<td>−0.03 (−0.06 to 0.00)</td>
<td>0.02 (−0.01 to 0.06)</td>
<td>0.00 (−0.04 to 0.04)</td>
</tr>
<tr>
<td>Log-triglycerides (mmol/l)</td>
<td>0.08 (0.07 to 0.09)*</td>
<td>0.07 (0.06 to 0.08)*</td>
<td>0.05 (0.04 to 0.06)*</td>
<td>0.04 (0.03 to 0.05)*</td>
</tr>
<tr>
<td>Log-C-reactive protein (mg/l)</td>
<td>−0.17 (−0.18 to −0.15)*</td>
<td>−0.12 (−0.14 to −0.11)*</td>
<td>−0.09 (−0.11 to −0.07)*</td>
<td>−0.15 (−0.17 to −0.13)*</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td>−0.32 (−0.38 to −0.27)*</td>
<td>−0.25 (−0.30 to −0.19)*</td>
<td>−0.13 (−0.20 to −0.07)*</td>
<td>−0.08 (−0.16 to −0.01)†</td>
</tr>
</tbody>
</table>

NFBC, Northern Finland Birth Cohort; Log, natural logarithmic transformation; all P > 0.05 except: *P < 0.001, †P < 0.05.

supplementary data given at the end of this article). The relation of SHBG with these cardiovascular risk factors, independently of TT, tended to be graded and linear (except for LDL-cholesterol). The online Supplementary Table S1 also shows the magnitude of the difference in risk. For example, those in the top fourths of SHBG distribution had lower systolic BP by 2.8 (95% CI 1.0–4.5) mmHg, diastolic BP by 3.7 (2.1 to 5.2) mmHg, and total cholesterol by 0.16 (95% CI 0.03–0.30) mmol/l as compared with those in the bottom fourths.

Testosterone and cardiovascular risk factors

After adjusting for smoking, education, physical activity and fasting insulin, increasing TT was significantly associated with decreasing BP, triglycerides and CRP, and increasing HDL-cholesterol as given in Table 4 (all P for trend <0.05). Adjusting for insulin and adiposity attenuated the associations, but further adjustment for SHBG changed the direction of the slope of the association between TT and the outcome measures (except for CRP). With adjustment for SHBG, increasing TT was associated with increasing BP, total and LDL-cholesterol, and triglycerides as well as with decreasing CRP (all P for trend <0.05); however, the relation with HDL-cholesterol was no longer significant. Findings were similar after substituting insulin with HOMA-IR in the regression model for all cardiovascular risk factors considered in this study.

When fasting insulin was used as an outcome variable, higher TT was associated with lower fasting insulin levels even after adjusting for adiposity and other covariates (P=0.007), but this association did not persist when SHBG was taken into account (P > 0.05).

Figures 1 and 2 show the relative difference in BP and lipids across the whole gradient of TT after adjusting for SHBG and other covariates (full values are shown in the supplementary data given at the end of this article). The relation of SHBG with these cardiovascular risk factors, independently of TT, tended to be graded and linear (except for LDL-cholesterol). The online Supplementary Table S1 also shows the magnitude of the difference in risk. For example, those in the top fourths of SHBG distribution had lower systolic BP by 2.8 (95% CI 1.0–4.5) mmHg, diastolic BP by 3.7 (2.1 to 5.2) mmHg, and total cholesterol by 0.16 (95% CI 0.03–0.30) mmol/l as compared with those in the bottom fourths.

Testosterone and cardiovascular risk factors

After adjusting for smoking, education, physical activity and fasting insulin, increasing TT was significantly associated with decreasing BP, triglycerides and CRP, and increasing HDL-cholesterol as given in Table 4 (all P for trend <0.05). Adjusting for insulin and adiposity attenuated the associations, but further adjustment for SHBG changed the direction of the slope of the association between TT and the outcome measures (except for CRP). With adjustment for SHBG, increasing TT was associated with increasing BP, total and LDL-cholesterol, and triglycerides as well as with decreasing CRP (all P for trend <0.05); however, the relation with HDL-cholesterol was no longer significant. Findings were similar after substituting insulin with HOMA-IR in the regression model for all cardiovascular risk factors considered in this study.

When fasting insulin was used as an outcome variable, higher TT was associated with lower fasting insulin levels even after adjusting for adiposity and other covariates (P=0.007), but this association did not persist when SHBG was taken into account (P > 0.05).

Figures 1 and 2 show the relative difference in BP and lipids across the whole gradient of TT after adjusting for SHBG and other covariates (full values are shown in the supplementary data given at the end of this article). The relation of SHBG with these cardiovascular risk factors, independently of TT, tended to be graded and linear (except for LDL-cholesterol). The online Supplementary Table S1 also shows the magnitude of the difference in risk. For example, those in the top fourths of SHBG distribution had lower systolic BP by 2.8 (95% CI 1.0–4.5) mmHg, diastolic BP by 3.7 (2.1 to 5.2) mmHg, and total cholesterol by 0.16 (95% CI 0.03–0.30) mmol/l as compared with those in the bottom fourths.

Testosterone and cardiovascular risk factors

After adjusting for smoking, education, physical activity and fasting insulin, increasing TT was significantly associated with decreasing BP, triglycerides and CRP, and increasing HDL-cholesterol as given in Table 4 (all P for trend <0.05). Adjusting for insulin and adiposity attenuated the associations, but further adjustment for SHBG changed the direction of the slope of the association between TT and the outcome measures (except for CRP). With adjustment for SHBG, increasing TT was associated with increasing BP, total and LDL-cholesterol, and triglycerides as well as with decreasing CRP (all P for trend <0.05); however, the relation with HDL-cholesterol was no longer significant. Findings were similar after substituting insulin with HOMA-IR in the regression model for all cardiovascular risk factors considered in this study.

When fasting insulin was used as an outcome variable, higher TT was associated with lower fasting insulin levels even after adjusting for adiposity and other covariates (P=0.007), but this association did not persist when SHBG was taken into account (P > 0.05).
The relation of TT with these cardiovascular risk factors tended to be graded and linear (except for HDL-cholesterol). The online Supplementary Table S2 also gives the magnitude of the difference in risk. For example, those in the top fourths of TT distribution had higher systolic BP by 0.7 (95% CI 0.2–1.2) mmHg, diastolic BP by 0.8 (95% CI 0.3–1.2) mmHg and total cholesterol by 0.12 (95% CI 0.08–0.16) mmol/l as compared with those in the bottom fourths.

After adjusting for smoking, education, physical activity, fasting insulin, BMI and waist circumference, increasing cFT was significantly and positively related to BP, total cholesterol and triglycerides (online Supplementary Table S3). The direction and magnitude of the associations with the various risk factors were similar to those of covariate- and SHBG-adjusted associations for TT, except for CRP wherein the magnitude of the reduction in CRP was twice as big as the association seen for cFT. For example, a one quartile increase in TT (5.2 nmol/l) and cFT (110 pmol/l) was associated with an increase in systolic BP by 0.7 (95% CI 0.2–1.2) and 0.6 (0.2–1.1) respectively; and an increase in cholesterol by 0.12 (95% CI 0.08–0.16) and 0.10 (0.07–0.14) respectively.

Discussion

In this cohort of young adult men, increasing serum SHBG concentration was generally associated with a better cardiovascular risk profile. Higher SHBG concentration was associated with lower BP, cholesterol, triglycerides and CRP as well as higher HDL-cholesterol, independently of TT, insulin, adiposity and other potential confounding factors. The magnitude of the association varied across CVD risk factors, but the associations were largely linear.
across a wide range of SHBG concentration in this population. Our findings suggest that SHBG may primarily play a role in the cardiovascular health of young men through a number of mediating biological risk factors.

Many studies have previously investigated the separate relation of SHBG with different CVD risk factors (online Supplementary Tables S4 and S5, see section on supplementary data given at the end of this article), but findings in men, particularly of sufficient sample size, remain relatively limited (few studies had \( n > 1000 \)). Considering that CVD can involve a number of biological pathways, few studies considered examining a number of risk factors from within a single cohort (15, 19, 35, 36, 37). Many of the earlier studies have also not accounted for the potential confounding effects of adiposity and insulin. Considering that SHBG and TT concentrations co-vary with one other, it is unclear if findings for SHBG are simply explained by TT. Our study is based on a relatively large sample of young men with a very narrow age range (same year of birth). We examined associations across a number of classical and non-classical risk factors of CVD, and systematically took into account important covariates, such as adiposity and insulin, as well as TT. Our results persisted even when we substituted insulin with HOMA-IR as a covariate in our analyses.

Over 40% of TT in the circulation is bound with strong affinity to SHBG concentration in men and most of the remaining testosterone is loosely bound to albumin, with only 1–2% of that circulating as biologically active FT (38). However, direct measures of FT from blood samples for large cohorts are not feasible to do, so it is only estimated from simple, quantitative methods based on the law of mass action (32). Thus, cFT has been suggested to provide an estimate of the biologically active form of testosterone with reasonable accuracy (38). Because SHBG has been traditionally seen to only have a passive role as a carrier protein, and that TT correlates with and explains over 80% of the variance of FT (39), TT is widely used in many studies that examine the importance of testosterone on health in population-based studies.

However, SHBG could have a biological function on its own other than simply to regulate the levels of the biologically active fraction of testosterone (4). As our findings suggest, it may be involved in the determination of cardiovascular risk, although the underlying mechanism is unclear. As the relation of SHBG with CVD risk factors was independent of testosterone, other pathways could be involved. A study that identified genetic variants associated with SHBG concentration indicates that these genes are likely to be involved in various metabolic pathways, such as lipid and carbohydrate metabolism, liver function and type 2 diabetes (40). It is possible that the association between SHBG and CVD risk factors may have nothing to do with the role of SHBG as testosterone carrier; it responds to a number of metabolic alterations and its concentration may reflect these metabolic perturbations.

Our study has also shown interesting findings for testosterone. Although it has been suggested to play direct and indirect roles in lipid metabolism, regulation of BP and immunomodulation (41, 42, 43, 44, 45, 46, 47), reports on the relationship between testosterone and CVD or its risk factors have been inconsistent (41, 48, 49, 50), and possibly confounded (51). The conflicting findings, particularly between endogenous testosterone and CVD risk factors, could stem from the fact that many studies used the biologically inactive rather than the bioavailable fraction of testosterone (without accounting for the potential influence of SHBG and other potential confounders). In our study, we demonstrated the change in the magnitude and direction of the association of TT with cardiovascular risk factors (except for HDL-cholesterol and CRP) by systematically taking into account various lifestyle factors, insulin, adiposity and SHBG. Because SHBG regulates the availability of the active fraction of testosterone, the SHBG-adjusted associations for TT could be indicative of the effects of biologically active FT (as shown by the results for cFT). Nevertheless, age might modify the association between testosterone and CVD risk, which seems to suggest that higher testosterone could be associated with increased CVD risk in younger men, as we have observed in our cohort, but potentially the reverse is true in older men (48).

It has been shown that ageing and subclinical chronic diseases that are prevalent in older men are associated with reduced testosterone levels (52). Thus, low testosterone may indicate poor underlying health status and may be predictive of adverse health risks in older men (48, 49), but the reverse may be the case in young men.

Interestingly, TT was independently but inversely related with CRP, an association which differed from that of other biological risk markers. This relationship might reflect the effect of androgens in inhibiting the synthesis of pro-inflammatory cytokines, including tumour necrosis factor-\( \alpha \) and interleukin-6 (44, 53), which may consequently attenuate the production of downstream markers of inflammation such as CRP.

The recent identification of genetic markers associated with circulating levels of TT found in the SHBG locus (54) could shed light on the nature of the association between TT and CVD risk factors. In a recent study, the association
between lower TT and CVD risk factors has been investigated using two different analytical approaches (51). On the basis of multivariate regression models (but without adjusting for SHBG, adiposity and insulin as we did in our study), low TT was associated with a more adverse CVD risk profile. In contrast, when using genetic variants of TT as instruments in an instrumental variable analysis (Mendelian randomisation), most of the associations weakened in magnitude and were no longer significant, with the slope of the associations possibly changing in their direction. For example, the regression analysis results showed a significant inverse relationship between TT and systolic BP; in contrast, the instrumental variable analyses suggested a significant positive relationship between TT and systolic BP. Such observations were similar to our findings when we adjusted for various covariates including SHBG (although in their analyses they did not adjust for insulin and adiposity).

The cross-sectional design of this study does not allow us to demonstrate the temporal nature of the associations, and a longitudinal study is warranted. Our findings need to be evaluated across a wider age range, as ageing is related to changing in their direction. For example, the regression analysis results showed a significant inverse relationship between TT and systolic BP; in contrast, the instrumental variable analyses suggested a significant positive relationship between TT and systolic BP. Such observations were similar to our findings when we adjusted for various covariates including SHBG (although in their analyses they did not adjust for insulin and adiposity).

Understanding the role of SHBG in these different pathways might provide clues to the biological basis for explaining the relationship of SHBG and CVD risk factors.
Sex differences in the associations of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in middle-aged and elderly Korean men.

D Canoy and others

SHBG and cardiovascular disease risk

European Journal of Endocrinology

170:6

871


37 Kweon SS, Shin MH, Nam HS, Jeong SK, Park KS, Choi JS & Lee YH. Sex differences in the associations of testosterone and sex hormone-binding globulin with metabolic syndrome in middle-aged and elderly men.


57 Vermeulen A, Kaufman JM & Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. *Journal of Clinical Endocrinology and Metabolism* 1996 81 1821–1826. (doi:10.1210/jcem.81.5.8626841)


Received 20 December 2013
Revised version received 7 March 2014
Accepted 26 March 2014